News
LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...
14h
News-Medical.Net on MSNAffordable HIV drug shows promise in improving vision for diabetic eye diseaseAn inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly ...
An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
12h
Woman's World on MSNHigh Blood Sugar Can Affect Your Eyes: Early Signs of Diabetic RetinopathyThanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...
The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...
A study by the Journal of the American Medical Association found that weight loss in middle age can decrease all-cause ...
An oral drug that improves vision in DME [diabetic macular edema] would be a game changer because it would be more ...
Ocugen ( NASDAQ: OCGN) disclosed on Tuesday that its gene therapy candidate, OCU410ST, has been granted rare pediatric ...
Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results